Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Xortx Therapeutics Inc. currently manages 1 pending office action. This matter is located within the Biotechnology & Pharmaceuticals technology area. Having 1 pending office action suggests a focused prosecution phase for the company's current intellectual property interests.
The examination involves 1 distinct examiner and 1 distinct art unit. This concentration in 1 distinct art unit means the technical evaluation is confined to a specific regulatory group. HUANG, GIGI GEORGIANA is the busiest examiner for this company and is responsible for 1 pending office action, which matches the total count of pending actions for the portfolio.
Because there is 1 distinct examiner, the company's immediate patent outcomes depend on the specific review style of HUANG, GIGI GEORGIANA. The 1 pending office action in the Biotechnology & Pharmaceuticals sector requires a response tailored to this examiner's history. Managing the prosecution with 1 examiner allows for a direct legal strategy without the need to coordinate across different art units.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| HUANG, GIGI GEORGIANA | 1 | 31.8% | +30.8% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17818159 | XANTHINE OXIDASE INHIBITOR FORMULATIONS | HUANG, GIGI GEORGIANA | 14d |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17818159 | XANTHINE OXIDASE INHIBITOR FORMULATIONS | HUANG, GIGI GEORGIANA | 14d |
| Art Unit | Apps |
|---|---|
| 1613 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 17818159 | XANTHINE OXIDASE INHIBITOR FORMULATIONS | HUANG, GIGI GEORGIANA | 1613 | §101§102§103§112Other | Final Rejection | 14d | Pending | Aug 08, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial